Form 4: UNITED THERAPEUTICS CEO Sells Shares
Insider Transaction (Form 4)
Martine A Rothblatt, Chairperson & CEO and a Director of UNITED THERAPEUTICS Corp, sold 9,500 shares of common stock on September 29, 2026.
Summary
- Option exercise/conversion: acquired 9,500 Common Stock at $117.76 ($1,118,720) on September 29, 2026; holds 333,943 after (Indirect).
- Open-market sale: disposed of 400 Common Stock at $472.05 ($188,818) on September 29, 2026; holds 333,543 after (Indirect).
- Open-market sale: disposed of 449 Common Stock at $472.97 ($212,363) on September 29, 2026; holds 333,094 after (Indirect).
- Open-market sale: disposed of 80 Common Stock at $473.86 ($37,908) on September 29, 2026; holds 333,014 after (Indirect).
- Open-market sale: disposed of 552 Common Stock at $475.12 ($262,263) on September 29, 2026; holds 332,462 after (Indirect).
- Open-market sale: disposed of 1,395 Common Stock at $476.10 ($664,160) on September 29, 2026; holds 331,067 after (Indirect).
- Open-market sale: disposed of 2,135 Common Stock at $477.09 ($1,018,581) on September 29, 2026; holds 328,932 after (Indirect).
- Open-market sale: disposed of 2,309 Common Stock at $478.10 ($1,103,923) on September 29, 2026; holds 326,623 after (Indirect).
- Open-market sale: disposed of 1,200 Common Stock at $479.07 ($574,889) on September 29, 2026; holds 325,423 after (Indirect).
- Open-market sale: disposed of 160 Common Stock at $479.59 ($76,734) on September 29, 2026; holds 325,263 after (Indirect).
- Open-market sale: disposed of 500 Common Stock at $481.22 ($240,612) on September 29, 2026; holds 324,763 after (Indirect).
- Open-market sale: disposed of 120 Common Stock at $482.28 ($57,874) on September 29, 2026; holds 324,643 after (Indirect).
- Open-market sale: disposed of 200 Common Stock at $486.77 ($97,354) on September 29, 2026; holds 324,443 after (Indirect).
- Option exercise/conversion: disposed of 9,500 Stock Option on September 29, 2026; holds 337,910 after (Indirect).
Sentiment
Score: 4
Explanation: StockSavvy.ai views this as a mildly negative but low-conviction signal: an insider sold $4,535,480 of stock under a pre-arranged Rule 10b5-1 plan, which is typically routine.
Insider Transactions
Martine A Rothblatt — Director, Officer (Chairperson & CEO)
Transaction made under a Rule 10b5-1 trading plan.
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-09-29 | Option exercise/conversion | Common Stock | 9,500 | $118 | $1.1M | 333,943 |
| 2026-09-29 | Open-market sale | Common Stock | 400 | $472 | $188.8K | 333,543 |
| 2026-09-29 | Open-market sale | Common Stock | 449 | $473 | $212.4K | 333,094 |
| 2026-09-29 | Open-market sale | Common Stock | 80 | $474 | $37.9K | 333,014 |
| 2026-09-29 | Open-market sale | Common Stock | 552 | $475 | $262.3K | 332,462 |
| 2026-09-29 | Open-market sale | Common Stock | 1,395 | $476 | $664.2K | 331,067 |
| 2026-09-29 | Open-market sale | Common Stock | 2,135 | $477 | $1.0M | 328,932 |
| 2026-09-29 | Open-market sale | Common Stock | 2,309 | $478 | $1.1M | 326,623 |
| 2026-09-29 | Open-market sale | Common Stock | 1,200 | $479 | $574.9K | 325,423 |
| 2026-09-29 | Open-market sale | Common Stock | 160 | $480 | $76.7K | 325,263 |
| 2026-09-29 | Open-market sale | Common Stock | 500 | $481 | $240.6K | 324,763 |
| 2026-09-29 | Open-market sale | Common Stock | 120 | $482 | $57.9K | 324,643 |
| 2026-09-29 | Open-market sale | Common Stock | 200 | $487 | $97.4K | 324,443 |
| 2026-09-29 | Option exercise/conversion | Stock Option | 9,500 | — | — | 337,910 |
Key Dates
| Date | Description |
|---|---|
| 2026-09-29 | Option exercise/conversion (9,500 shares) |
| 2026-09-29 | Open-market sale (400 shares) |
| 2026-09-29 | Open-market sale (449 shares) |
| 2026-09-29 | Open-market sale (80 shares) |
| 2026-09-29 | Open-market sale (552 shares) |
| 2026-09-29 | Open-market sale (1,395 shares) |
| 2026-09-29 | Open-market sale (2,135 shares) |
| 2026-09-29 | Open-market sale (2,309 shares) |
| 2026-09-29 | Open-market sale (1,200 shares) |
| 2026-09-29 | Open-market sale (160 shares) |
| 2026-09-29 | Open-market sale (500 shares) |
| 2026-09-29 | Open-market sale (120 shares) |
| 2026-09-29 | Open-market sale (200 shares) |
| 2026-09-29 | Option exercise/conversion (9,500 shares) |
Keywords
insider transaction, Form 4, UTHR, UNITED THERAPEUTICS Corp, bearish, Martine A Rothblatt
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.